Haijun Dong – CEO, BioDuro-Sundia
Dr Haijun Dong, recently appointed CEO of BioDuro-Sundia, shares his priorities for the newly merged entity, one of the largest Contract Research,…
Tagged with M&A
Thomas A. Tóth von Kiskér – CEO & Board Member,…
Thomas A. Tóth von Kiskér, longstanding CEO of Tillotts Pharma AG, a Switzerland-based specialty pharma player focused on the digestive system,…
Viatris: Cost-Cutting Needed at New Generics Behemoth
In November 2020, after months of delay caused by COVID-19 disruptions and a US antitrust roadblock, Mylan and Pfizer's Upjohn generics unit finally…
J&J’s Momenta Deal A Further Sign of Big Pharma’s Rare…
In the wake of Sanofi’s USD 3.7 billion tie-up for US biotech Principia, J&J has moved to bolster its autoimmune portfolio with the acquisition…
Sanofi Buys Principia for USD 3.7 Billion as Part of Specialty…
Sanofi has agreed a deal to buy out its partner, US biotech company Principia Biopharma for USD 3.7 billion in cash, giving the French giant full…
Korean Celltrion Makes First Big Global Move with Acquisition of…
Korean biosimilar firm Celltrion's USD 266 million acquisition of Japanese outfit Takeda assets in the Asia-Pacific region marks a significant moment…
Menarini Makes Big US Oncology Move with Stemline Acquisition
Menarini Group, the largest Italian pharmaceutical company by turnover, has made its first move into the US oncology market through the acquisition of…
Company Spotlight: BMS Romania
With the 2019 acquisition of Celgene – one of the largest pharma acquisition in history – two of the sector’s most innovative oncology companies…
Dominika Kovacs – Country Manager, Takeda Romania
Dominika Kovacs, country manager of Takeda Romania, shares her insights on the growing pipeline of the organisation and the anticipated launch of a…
Kieran Leahy – General Manager, Takeda Czech Republic…
Kieran Leahy, general manager of Takeda in the Czech Republic and Slovakia, recounts how he has led the transformation of Takeda into a specialty care…
Life Sciences’ Growing Demand for AI Assets
Digital health deal values in biopharma jumped to USD 6.4 billion in 2019, largely thanks to software company Dassault Systemes Americas Corp.'s USD…
A Pharma Funding Overview & Outlook for 2020
Michael Jewell, partner and head of healthcare & life sciences at Cavendish Corporate Finance looks back at the key trends across pharma industry…
